Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07489612
PHASE2

QLS1410 in Participants With Uncontrolled Hypertension

Sponsor: Qilu Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to measure the efficacy and safety of QLS1410 in participants with uncontrolled hypertension (uHTN) or treatment-resistant hypertension (rHTN). The main objective is to compare the difference in systolic blood pressure(SBP) change from baseline at Week 12 of treatment between participants receiving QLS1410 tablets and participants receiving placebo tablets.

Official title: A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of QLS1410 in Participants With Uncontrolled Hypertension

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

260

Start Date

2026-04

Completion Date

2027-03

Last Updated

2026-03-24

Healthy Volunteers

No

Interventions

DRUG

Dose 1 of QLS1410

QLS1410 tablet administered orally, once daily (QD).

DRUG

Dose 2 of QLS1410

QLS1410 tablet administered orally, once daily (QD).

DRUG

Dose 3 of QLS1410

QLS1410 tablet administered orally, once daily (QD).

DRUG

placebo

Matching placebo tablet administered orally, once daily (QD).